Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: A retrospective cohort study

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Sapra, Sandhya ^a   Chang, Eunice ^b   Broder, Michael S ^b   L'Italien, Gilbert ^a,c  

^a BRISTOL MYERS SQUIBB   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Insurance claims; Pegylated interferon alpha; Retrospective study; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

COMORBIDITY; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEPATITIS C, CHRONIC; HUMAN; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INSURANCE, HEALTH; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84907467426     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-429     Document Type: Article

References (34)

1. The global burden of hepatitis C. Lavanchy D, Liver Int 2009 29 Suppl 1 74 81
2. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F, Hepatology 2005 41 790 800
3. Overcoming barriers to care for hepatitis C. Clark PJ, Muir AJ, N Engl J Med 2012 366 2436 2438
4. Public health impact of antiviral therapy for hepatitis C in the United States. Volk ML, Tocco R, Saini S, Lok AS, Hepatology 2009 50 1750 1755
5. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ, Ann Intern Med 2006 144 705 714
6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 975 982
7. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965
8. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M, Gastroenterology 2010 139 1593 1601
9. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL, Ann Intern Med 2007 147 677 684
10. Side effects of therapy of hepatitis C and their management. Fried MW, Hepatology 2002 36 237 S244
11. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK, Gastroenterology 2002 123 1061 1069
12. Interferon-alfa, interferon-lambda and hepatitis C. O'Brien TR, Nat Genet 2009 41 1048 1050
13. Boceprevir for untreated chronic HCV genotype 1 infection. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators, N Engl J Med 2011 364 1195 1206
14. Telaprevir for previously untreated chronic hepatitis C virus infection. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team, N Engl J Med 2011 364 2405 2416
15. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA, Clin Gastroenterol Hepatol 2010 8 972 978
16. Hepatitis C treatment completion rates in routine clinical care. Butt AA, McGinnis KA, Skanderson M, Justice AC, Liver Int 2010 30 240 250
17. PriceRx Pro [electronic database]. Wolters Kluwer Health. Average Wholesale Price, 2013 https://pricerx.medispan.com. Accessed 9/27/2013
18. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ, JAMA 2003 290 228 237
19. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V, Value Health 2010 13 479 486
20. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Zeuzem S, Nat Clin Pract Gastroenterol Hepatol 2008 5 610 622
21. PegIntron (peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use [package insert] Whitehouse Station, NJ: Merck & Co., Inc 2011
22. PEGASYS (peginterferon alfa-2a) Injection for Subcutaneous Use [package insert]. Package Insert South San Francisco, CA: Genentech, Inc 2011
23. COPEGUS® (ribavirin) tablets [package insert] South San Francisco, CA: Genentech, Inc 2011
24. Ribasphere® (ribavirin, USP) tablets [package insert] New York, NY: Kadmon Pharmaceuticals 2012
25. Out-of-pocket medical spending for care of chronic conditions. Hwang W, Weller W, Ireys H, Anderson G, Health Aff (Millwood) 2001 20 267 278
26. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. Papatheofanis F, Bookhart BK, Muser E, Piech CT, J Occup Environ Med 2008 50 584 589
27. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Kimel M, Leidy NK, Mannix S, Dixon J, Value Health 2008 11 57 75
28. Health and disability costs of depressive illness in a major U.S. corporation. Druss BG, Rosenheck RA, Sledge WH, Am J Psychiatry 2000 157 1274 1278
29. The direct and indirect costs of untreated insomnia in adults in the United States. Ozminkowski RJ, Wang S, Walsh JK, Sleep 2007 30 263 273
30. Persistence with hepatitis C therapy in the Department of Veterans Affairs. Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L, J Clin Pharm Ther 2008 33 251 261
31. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH, Ann Intern Med 1996 125 634 639
32. Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Hyams KC, Riddle J, Rubertone M, Trump D, Alter MJ, Cruess DF, Han X, Nainam OV, Seeff LB, Mazzuchi JF, Bailey S, Am J Epidemiol 2001 153 764 770
33. Diagnosis, management, and treatment of hepatitis C. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases, Hepatology 2004 39 1147 1171
34. Telaprevir for retreatment of HCV infection. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, N Engl J Med 2011 364 2417 2428